Clinical trials: Contraceptive Devices
Pharmacokinetics
Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects
The purpose of this study is to evaluate the effect of repeated doses of AZD7325 on the pharmacokinetics of ORTHO-CYCLEN, a monophasic oral contraceptive
- Trial name
- NCT00901290
- Testing
- monophasic oral contraceptive, AZD7325
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants
The purpose of this study is to evaluate the effect of multiple doses of BMS-986322 on the pharmacokinetics (PK) of Loestrin components in healthy female participants.
- Trial name
- NCT05579574
- Testing
- BMS-986322, Loestrin
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Women, Contraception
Annovera™ Drug-Drug Interaction Study
A Drug-Drug Interaction (DDI) study to evaluate the effects of itraconazole and rifampin on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol from the Annovera Contraceptive Vaginal System (CVS)
- Trial name
- NCT04290390
- Testing
- Segesterone Acetate and Ethinyl Estradiol, Rifampin, Itraconazole
- Where
- Canada
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- TherapeuticsMD
Contraceptive, Oral, Hormonal
Cycle Control and Safety of E2-DRSP
The study will be performed as a multi-center, randomized, double-blind, parallel-group trial in fertile women aged between 18 and 35 years inclusive.
- Trial name
- NCT00653614
- Testing
- E2/DRSP (BAY 86-4891) dose 1 (SH T04984E), E2/DRSP (BAY 86-4891) dose 2 (80458739), E2/DRSP (BAY 86-4891) dose 3 (80458755)
- Where
- 25 sites in Germany
- Volunteers
- 635 people
- Sponsor
- Bayer
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females
This trial is conducted in Europe. The aim of the trial is to investigate the influence of oral semaglutide on pharmacokinetics (the exposure of the trial drug in the body) of ethinylestradiol and levonorgestrel in an oral…
- Trial name
- NCT02845219
- Testing
- semaglutide, SNAC, Microgynon®
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Contraception
A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)
The purpose of this study is to demonstrate that a new device inserter leads to successful and safe insertion of Paragard® IUS, comparable to the currently approved IUS inserter, in females of reproductive potential.
- Trial name
- NCT05309694
- Testing
- Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
- Where
- 8 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- CooperSurgical Inc.
Contraception
A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)
An open-label, randomized, parallel group trial in healthy female subjects to compare the pharmacokinetics of ethinyl estradiol (EE) of NuvaRing®, a contraceptive patch (EVRA(TM)) and an oral contraceptive (Microgynon® 30).
- Trial name
- NCT01044056
- Testing
- Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets, norelgestrominum and ethinylestradiol patch oral contraceptive patch, Nuvaring ™ (etonorgestrel/ethinylestradiol)
- Volunteers
- 24 people
- Sponsor
- Organon and Co
Healthy
A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021
This is a multi-center study to evaluate hormone levels with the oral contraceptive regimen DR-1021.
- Trial name
- NCT00544882
- Testing
- DR-1021, Mircette®, Kariva®
- Where
- 4 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Systemic Lupus Erythematosus, Arthritic Psoriasis
The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients.
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03262727
- Testing
- BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Contraception
Mirena Extension Trial
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding…
- Trial name
- MET (NCT02985541)
- Testing
- Levonorgestrel IUS (Mirena, BAY86-5028)
- Where
- 49 sites in United States
- Volunteers
- 364 people
- Sponsor
- Bayer
Tuberculosis
A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential
This study is designed to assess the pharmacokinetics (PK), safety, and tolerability of Ganfeborole and Microgynon, an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG), when Microgynon is administered…
- Trial name
- NCT07784894
- Testing
- Ganfeborole, Microgynon
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contraception
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Cyclofem® is a monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C), a long-acting ester of estradiol.
- Trial name
- NCT01699022
- Testing
- Injection Cyclofem
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries Limited
Contraception
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
The primary objective is to assess the safety profile of YAZ in Chinese women, including adverse drug reactions (ADRs). The secondary objectives are to investigate the rate of unintended pregnancies, the cycle control for…
- Trial name
- NCT02710708
- Testing
- EE20/DRSP (YAZ, BAY86-5300)
- Where
- 38 sites in China
- Volunteers
- 1,921 people
- Sponsor
- Bayer
Contraception
Efficacy and Safety Oral Contraceptive Study
The purpose of this study is to determine whether the study drug is effective in prevention of pregnancy in healthy women in reproductive age
- Trial name
- NCT00185484
- Testing
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- Bayer
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
This open-label, randomized, cross-over study evaluated the effect of tocilizumab (TCZ) on the pharmacokinetics and pharmacodynamics of a common oral contraceptive (OC) in female patients with active rheumatoid arthritis (RA) and…
- Trial name
- NCT01044498
- Testing
- Tocilizumab, Ortho-Novum® 1/35
- Where
- 6 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Breakthrough Bleeding
A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale
This is a 4-arm study to evaluate and compare bleeding patterns between three different doses of DR-1031 oral contraceptive with Seasonale oral contraceptive.
- Trial name
- NCT00394771
- Testing
- DR-1031, Seasonale®, Portia®
- Where
- 50 sites in United States
- Volunteers
- 567 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight.
- Trial name
- NCT07808060
- Testing
- Eloralintide, Combined oral contraceptive
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Emergency Contraception
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.
The purposes of this study are to compare the effects on ovarian activity of quick starting a Combined Oral Contraceptive Pill (COCP) after ellaOne® or placebo intake.
- Trial name
- NCT01569113
- Testing
- Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Healthy
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
This study is open to women with overweight or obesity who are otherwise healthy. Women with a body mass index (BMI) from 27 to 40 kg/m2 can participate.
- Trial name
- NCT05896384
- Testing
- BI 456906, Microgynon®
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Contraception
Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)
The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function.
- Trial name
- NCT00511433
- Testing
- NOMAC-E2, DRSP-EE
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Organon and Co